ArticleSubstance abuse : research and treatment2017
Access to and Payment for Office-Based Buprenorphine Treatment in Ohio.
Article in Substance abuse : research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Multi-level barriers and facilitators to buprenorphine use in Ontario, Canada: a qualitative study using the theoretical domains framework.Addiction science & clinical practice · 2025Article
- Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.Journal of substance use and addiction treatment · 2024Article
- Multidimensional assessment of access to medications for opioid use disorder across urban and rural communities: A scoping review.The International journal on drug policy · 2023Article
- 'It's the same thing as giving them CPR training': rural first responders' perspectives on naloxone.Harm reduction journal · 2022Article
- Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.Drug and alcohol dependence · 2022Article
- Pharmacists and opioid use disorder care during COVID-19: Call for action.Journal of the American College of Clinical Pharmacy : JACCP · 2022Article
- Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.JAMA network open · 2021Article
- Federally Qualified Health Centers Can Expand Rural Access to Buprenorphine for Opioid Use Disorder in Arizona.Health services insights · 2021Article
- Knowledge, preparedness, and compassion fatigue among law enforcement officers who respond to opioid overdose.Drug and alcohol dependence · 2020Article
- Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.Journal of general internal medicine · 2020Review
- "You are not clean until you're not on anything": Perceptions of medication-assisted treatment in rural Appalachia.The International journal on drug policy · 2020Article
- Disparities in Opioid Use Disorder Treatment Admissions.Journal of health economics and outcomes research · 2020Article
- Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.BMJ open · 2019Article
- Stigma as a fundamental hindrance to the United States opioid overdose crisis response.PLoS medicine · 2019Article
- Buprenorphine Treatment Divide by Race/Ethnicity and Payment.JAMA psychiatry · 2019Article
- Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study.Annals of internal medicine · 2019Article
- Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis.American journal of public health · 2019Article
- Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.Substance abuse · 2019Article
- Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.Journal of psychoactive drugsArticle
- Patterns of Medication for Opioid Use Disorder During Pregnancy, 7 Clinical Sites, MATernaL and Infant clinical NetworK (MAT-LINK), 2014-2021.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceOffice-based opiate agonist therapy has dramatically expanded access to medication-assisted treatment over the past decade but has also led to increased buprenorphine diversion.
objectiveOur study sought to characterize physicians who participate in office-based therapy (OBT) to assess patient access to OBT in Ohio 10 years after its introduction. DESIGN/SETTING/
participantsCross-sectional telephone survey of Drug Addiction Treatment Act-waivered physicians in Ohio listed by the Center for Substance Abuse Treatment (CSAT). MAIN OUTCOMES: This study sought to determine what proportion of eligible physicians are actively prescribing buprenorphine, whether they accept insurance for OBT, and whether they accept insurance for non-OBT services. In addition, we evaluated what physician characteristics predicted those primary outcomes. We hypothesized that a significant minority of eligible physicians are not active prescribers of buprenorphine. In addition, we expected that a significant minority of OBT prescribers do not accept insurance, further restricting patient access. We further hypothesized that a large subset of OBT prescribers accept insurance in their regular practices but do not take insurance for OBT.
resultsOf the 466 listed physicians, 327 (70.2%) practice representatives were reached for interview. Thirty-three physicians were excluded, with a true response rate of 75.5%. In total, 80.7% of providers reached were active OBT prescribers. Of these, 52.7% accepted insurance for OBT, 20.8% accepted insurance for non-OBT services but not for OBT, and 26.5% did not accept insurance for any services. Practices who did not accept insurance were more likely among dedicated addiction clinics located outside of Ohio's 6 major cities. Practices who normally accepted insurance but did not for OBT services were more likely in urban locations and were not associated with dedicated addiction practices. Neither business practice was associated with physician specialty. CONCLUSIONS AND RELEVANCE: Access to OBT in Ohio is far lower than what the 466 listed physicians suggests. Nearly 1 in 5 of those physicians are not active OBT prescribers, and 1 in 2 active prescribers do not accept insurance for OBT. Further research is needed to determine whether practices who do not accept insurance provide care consistent with CSAT guidelines and whether such practice patterns contribute to buprenorphine diversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.